Appendix 3C – Update – Notification of buy-back 2024 Announcements . Financial . News . Regulatory 18.03.2024
CLINUVEL initiates on market share buy-back program 2024 Announcements . Corporate . Financial . News 14.03.2024
SCENESSE® efficacy in vitiligo: new case presented at AAD 2024 Announcements . Clinical . News . Regulatory 11.03.2024
SCENESSE® Presented at American Academy of Dermatology 2024 Announcements . News . Regulatory 08.03.2024
Notice of ceasing to be a substantial holder 2024 Announcements . Financial . News . Regulatory 05.03.2024
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine 2024 Announcements . Corporate . News 04.03.2024
SCENESSE® provides photoprotection, improves QoL in variegate porphyria 2024 Announcements . Clinical . News . Regulatory 04.03.2024
Appendix 3Z – Final Director’s Interest Notice 2024 Announcements . Financial . News . Regulatory 27.02.2024
CLINUVEL Investor Webinar Financial Results – December 2023 Half Year 2024 Announcements . Corporate . Financial . News 23.02.2024
CLINUVEL Delivers Increased Revenues, Solid Earnings in December 2023 Half Year 2024 Announcements . Financial . News . Regulatory 22.02.2024